Hsp90

Research Funded by Bay Area Lyme Foundation Identifies New Investigational Therapy Regimen Capable of Irreversibly Damaging Lyme Bacteria in Laboratory Tests

Retrieved on: 
Wednesday, November 1, 2023
Linda, Knowledge, Lyme disease, University of California, Davis, Stanford University, Infection, UC, Obesity, MD, University of North Carolina, Doctor of Philosophy, Research, Light, Protein, Duke University School of Medicine, Borrelia burgdorferi, Medicine, Hypertension, Immunotherapy, Bacteria, University, Cell Chemical Biology, Cancer, Hsp90, Cell wall, Patient, Tulane University, DNA, Fatigue, Pharmaceutical industry, Vaccine, Pharmacology

“Bay Area Lyme concentrates on funding innovative research, including projects where knowledge can be deployed from other areas of medicine.

Key Points: 
  • “Bay Area Lyme concentrates on funding innovative research, including projects where knowledge can be deployed from other areas of medicine.
  • He encouraged scientists to take cancer staging techniques and immunotherapy learnings from oncology and apply them to Lyme research.
  • Bay Area Lyme Foundation also funded University of North Carolina collaborator, Matt Redinbo , PhD’s research on HS-291; his lab’s crystallography work was instrumental in the discovery process.
  • Bay Area Lyme Foundation’s research grant program was made possible by the support from the Fairbairn Family, the Younger Family Fund, and Project Lyme .

Gain Therapeutics to Participate in Virtual Fireside Chat On Computational Biology in Drug Discovery with Key Opinion Leaders

Retrieved on: 
Wednesday, March 22, 2023
Computational biology, Software engineering, Hsp90, Partnership, University, Doctor of Philosophy, Drug discovery, Oppenheimer, ARCH Venture Partners, Computational science, Health, ICREA, ML, Autonomous University of Barcelona, Drug design, Computational chemistry, Chemistry, University of Barcelona, MCA, The Co Founder, Novartis, Machine learning, University of Washington Information School, Engineering, Vernalis, Artificial intelligence, Biology, AI, Research, Therapy, VC, Data science, Pharmaceutical industry, Medical device, Biochemistry, Numeracy, Physics

The fireside chat, titled “Computational Biology in Drug Discovery with Gain Therapeutics (GANX) CTO & Two Experts,” will take place on Wednesday, March 29, 2023 at 12:00 pm ET.

Key Points: 
  • The fireside chat, titled “Computational Biology in Drug Discovery with Gain Therapeutics (GANX) CTO & Two Experts,” will take place on Wednesday, March 29, 2023 at 12:00 pm ET.
  • He is an entrepreneur focused on applying machine learning (ML) and large scale computational methods to improve human health.
  • Prior to Valo Health, Brandon was the co-founder and Chief Technology Officer of Numerate, a leader in ML-driven computational small molecule drug design.
  • Dr. Barril has over 18 years of experience in computational chemistry and drug discovery.

Tarveda Therapeutics to Present Data from Phase 2 Study of PEN-221 at 2021 ASCO Annual Meeting

Retrieved on: 
Thursday, May 20, 2021
Oncology, Health, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Hsp90

The payload is retained and then released over time causing the anti-cancer payload to become active in the tumor.\nTarveda currently has two Pentarin\xc2\xae miniature drug conjugates in clinical trials.

Key Points: 
  • The payload is retained and then released over time causing the anti-cancer payload to become active in the tumor.\nTarveda currently has two Pentarin\xc2\xae miniature drug conjugates in clinical trials.
  • Its first clinical program, PEN-866, is the initial candidate from its Heat Shock Protein 90 (\xe2\x80\x9cHSP90\xe2\x80\x9d) binding miniature drug conjugate platform.
  • Up to 75% of solid tumors have activated HSP90, and small molecule drugs that target activated HSP90 have desirable binding properties in solid tumors.
  • For more information regarding Tarveda, go to: http://www.tarvedatx.com .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210520005288/en/\n'

Tarveda Therapeutics Publishes Preclinical Study Evaluating HSP90 Binding Miniature Drug Conjugate with Pan-PI3K Payload in Solid Tumors

Retrieved on: 
Tuesday, August 4, 2020
Research, Clinical trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, Hsp90, Cancer research, Antineoplastic drugs, Branches of biology, Clinical medicine, Medicine, Monoclonal antibodies, Hsp90 inhibitor, Heat shock protein 90kDa alpha (cytosolic), member A1

Tarveda Therapeutics, Inc. , a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin miniature drug conjugates, today announced the publication of its preclinical study evaluating its HSP90 binding miniature drug conjugate with a pan-PI3K payload, T-2143, in solid tumors.

Key Points: 
  • Tarveda Therapeutics, Inc. , a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin miniature drug conjugates, today announced the publication of its preclinical study evaluating its HSP90 binding miniature drug conjugate with a pan-PI3K payload, T-2143, in solid tumors.
  • Its first clinical program, PEN-866, is the initial candidate from its Heat Shock Protein 90 (HSP90) binding miniature drug conjugate platform.
  • Up to 75% of solid tumors have activated HSP90, and small molecule drugs that target activated HSP90 have desirable binding properties in solid tumors.
  • In addition to PEN-866, Tarveda is developing additional miniature drug conjugates on its HSP90 binding miniature drug conjugate platform to target other promising anti-cancer payloads such as kinase inhibitors and radioisotopes to solid tumors.

Tarveda Therapeutics to Present at Upcoming Conferences

Retrieved on: 
Thursday, July 30, 2020
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Hsp90, N-(2-Hydroxypropyl) methacrylamide, Heat shock protein, Antineoplastic drugs, Chemistry, Biology

Mr. Fromkin will also participate in a fireside chat at the BTIG Virtual Biotechnology Conference, occurring August 10-11, 2020.

Key Points: 
  • Mr. Fromkin will also participate in a fireside chat at the BTIG Virtual Biotechnology Conference, occurring August 10-11, 2020.
  • Tarvedas Pentarin miniature drug conjugates are designed to deeply penetrate solid tumors, selectively bind to the desired tumor targets and accumulate their anti-cancer payloads directly in tumor cells.
  • Tarveda currently has two Pentarin miniature drug conjugates in clinical trials.
  • Its first clinical program, PEN-866, is the initial candidate from its Heat Shock Protein 90 (HSP90) binding miniature drug conjugate platform.

Tarveda Therapeutics to Present Data from First in Human Study of PEN-866 at the 2020 AACR Virtual Annual Meeting

Retrieved on: 
Tuesday, April 21, 2020
Oncology, Health, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Cancer treatments, Clinical medicine, Chemotherapy, Hsp90, N-(2-Hydroxypropyl) methacrylamide, Antibody-drug conjugates, Loncastuximab tesirine, Pyrrolobenzodiazepine

The anti-cancer payload is retained in tumor and then released over time causing the anti-cancer payload to become active in the tumor.

Key Points: 
  • The anti-cancer payload is retained in tumor and then released over time causing the anti-cancer payload to become active in the tumor.
  • Tarveda currently has two Pentarin miniature drug conjugates in clinical trials.
  • Its first clinical program, PEN-866, is the initial candidate from HSP90 binding miniature drug conjugate platform.
  • PEN-866 has completed its Phase 1 dose escalation portion of its all comers trial in various types of solid tumors.

Tarveda Therapeutics to Present at the Cowen & Company 40th Annual Health Care Conference

Retrieved on: 
Tuesday, February 25, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Life sciences, Articles, Cancer treatments, Biotechnology, Antineoplastic drugs, Acrylamides, Monomers, N-(2-Hydroxypropyl) methacrylamide, Hsp90, Biopharmaceutical, Pyrrolobenzodiazepine, Targeted therapy

Tarveda Therapeutics, Inc. , a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin miniature drug conjugates, today announced that Drew Fromkin, President and Chief Executive Officer, will present at the Cowen & Company 40th Annual Health Care Conference, occurring March 2-4, 2020 in Boston.

Key Points: 
  • Tarveda Therapeutics, Inc. , a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin miniature drug conjugates, today announced that Drew Fromkin, President and Chief Executive Officer, will present at the Cowen & Company 40th Annual Health Care Conference, occurring March 2-4, 2020 in Boston.
  • The anti-cancer payload is retained in tumor and then released over time causing the anti-cancer payload to become active in the tumor.
  • Tarveda currently has two Pentarin miniature drug conjugates in clinical trials.
  • Its first clinical program, PEN-866, is its initial candidate from its Heat Shock Protein 90 (HSP90) binding miniature drug conjugate platform.

Tarveda Therapeutics Presents Data from the Phase 1 Portion of a Phase 1/2a Study of PEN-866 at the European Society for Medical Oncology (ESMO) Congress 2019

Retrieved on: 
Monday, September 30, 2019
Oncology, Health, Clinical trials, Pharmaceutical, Biotechnology, Hsp90, Monoclonal antibodies

Based on these results, we have progressed to an expansion cohort to determine the recommended Phase 2 dose.

Key Points: 
  • Based on these results, we have progressed to an expansion cohort to determine the recommended Phase 2 dose.
  • We are excited about the profile of PEN-866 for its development in solid tumors where new, effective treatments are truly needed.
  • The HSP90 miniature drug conjugate is designed with a slowly cleaving linker resulting in a sustained release of SN-38 in tumor.
  • The Phase 1 study established a MTD and assessed the safety, tolerability, pharmacokinetics and efficacy of PEN-866.

"Hijacked" Cell Response to Stress Reveals Promising Drug Targets for Blood Cancer

Retrieved on: 
Monday, July 23, 2018
Biology, RTT, Biotechnology, Induced stem cells, Carcinogenesis, HSF1, Stem cell, Cancer cell, Breast cancer, Hsp90, Cancer

"The cancer cells are sending into overdrive a system that helps healthy cells respond to stress."

Key Points: 
  • "The cancer cells are sending into overdrive a system that helps healthy cells respond to stress."
  • A drug blocking HSP90 is already in early clinical trials elsewhere, led by study co-investigator Gabriela Chiosis, PhD, as a treatment for breast cancer.
  • Aifantis says if further testing proves successful, the experimental drug, labeled PU-H71, could be quickly adapted for trials in T-ALL patients.
  • The study also found that no adverse effects resulted and healthy blood cell production was not interrupted when HSF1 was removed from mouse bone marrow stem cells.